Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights [Accessibility Statement] Skip Navigation- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -- Interim Ph2 data readouts on track: SURF302 expected by end of 1H'26 and BEACH301 in 2H '26 -- Cash, cash equivalents and marketable securities of $256.0 million at Q4 2025; runway through at least 2027 -CARLSBAD, Calif., Ma ...